Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Apple slashed on towering valuation, 'soft growth' outlook: 4 big analyst cuts

Published 2023-10-04, 10:32 a/m
© Reuters.
AAPL
-
EMR
-
IXIC
-
BGS
-
DCFCQ
-

Investing.com -- Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Apple, Emerson, Tritium DCFC, and B&G Foods.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Apple falls on KeyBanc downgrade

Apple (NASDAQ:AAPL) lost its Overweight rating at KeyBanc Wednesday morning, as reported in real-time on InvestingPro.

The downgrade to Sector Weight came on Apple's valuation, which is near an all-time high and is rich vs. the Nasdaq Index as well, in addition to potential challenges in U.S. sales; possibly overly optimistic expectations for international growth; and the analysts' belief that Apple's top- and bottom-line estimates are already fully valued.

KeyBanc noted:

"We believe in order to justify upside to AAPL shares, peak valuations need to be applied or its growth profile needs to inflect higher."

KeyBanc also expects "soft growth" in key regions, with a focus on the US, which accounts for about 37% of Apple's revenue. The analysts expect a fourth consecutive year-over-year decline in Q4/23, potentially extending into Q1/24. KeyBanc's fiscal 2024 revenue growth projection is 3.5%, while the Street consensus stands at over 6%.

Apple is set to report its Q4/23 earnings on Oct 26.

B&G Foods plunges on {{0||Piper Sandler}} downgrade

B&G Foods (NYSE:BGS) was falling nearly 11% in recent trading after Piper Sandler cut the Crisco purveyor to Underweight from Neutral and lowered its price target to $8.00 from $14.00 late Tuesday,

The analysts said that the company, which owns a wide variety of other food brands, is seeing US measured retail sales trends "running behind our expectations for 3Q23, as measured retail sales declines continue to accelerate."

The analysts also pointed to share-count dilution and higher interest expense, which it believes will dilute earnings per share, as well as "risk from trade inventory de-loading, as its volume declines could drive resets to retailer inventories and potentially shelf space allocations."

Shares were lately changing hands at $8.45.

InvestingPro | Outsmart the Market

Emerson slashed at UBS

UBS on Tuesday downgraded Emerson Electric (NYSE:EMR) to Neutral from Buy with a price target of $104.00 (from $97.00) as “valuation now screens full." The analysts commented:

While we believe consensus numbers are going higher, our concern is valuation with EMR trading at ~19x pro-forma F'24 EPS and we think multiple upside is capped due to outsized O&G exposure and unclear M&A valuation creation.

Tritium cut at Raymond James

Tritium DCFC (NASDAQ:DCFC) shares fell around 4% Tuesday after Raymond James downgraded the company to Market Perform from Outperform due to concerns about the company's recent complex financing, involving Series A convertible redeemable preference shares.

This financing, with potentially variable terms and multiple covenants, is seen as unnecessary complexity compared to a straightforward issuance of common shares. Furthermore, it provides only a short runway of six to nine months before requiring additional capital, which could lead to further dilution in the coming years, according to Raymond James.

***

Amid whipsaw markets and a slew of critical headlines, seize on the right timing to protect your profits: Always be the first to know with InvestingPro.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.